Innovate

Nitrosamine impurities form when unreported changes to a synthetic process create the right conditions for an unwanted reaction, as one pharmaceutical company learned when this exact scenario led to a global recall. The result was a recall of several hypertension, heartburn, and diabetes medications, and an investigation that reshaped how the industry thinks about impurity

Traditional methods for evaluating the immunotoxic potential of pharmaceuticals typically involve animal testing, which is time-consuming, costly, and raises ethical concerns. In response to these challenges, regulatory agencies, including the Food and Drug Administration (FDA), are actively encouraging the development and acceptance of alternative methods. FDA’s new guidance on dermal sensitisation The FDA has recently

Veterinary medicines are commonly used by veterinarians, farmers and pet owners to treat and prevent animal diseases. Like what is already in place for pharmaceutical products within ICH M7, a guideline is also available for veterinary medicinal products to ensure appropriate control of mutagenic impurities. The guideline provides a practical framework that is applicable to

New approach methodologies (NAMs) are non-animal methods – including in chemico/in vitro assays and in silico predictions – which are increasingly being used to assess the safety of cosmetic ingredients and products. A next generation risk assessment (NGRA) framework for skin sensitisation has recently been developed, and case studies highlighting the role of NAMs, defined

We are delighted to announce our participation in the Animal-Free Safety Assessment for Cosmetics (AFSA) Masterclass. Launched in March 2023, this free, online training programme is designed to build capacity and confidence in animal-free safety assessment of cosmetics and ingredients. Over the last three years, our scientists have helped to build a one-of-a-kind educational course

We are delighted to share our vital new article ‘Establishing best practice for the application and support of solubility purge factors’ which was recently published in Organic Process Research & Development (OPRD). The paper has been written by Lhasa Principal Scientist Michael Burns, alongside industry expert co-authors from AstraZeneca, GSK, Hoffman LaRoche and other forward

Mutagenic impurities can be expected in any drug product; however, this is not a concern providing they are present below the safe limit. The objective of a carcinogenicity study is to identify compounds that can cause tumours in animals, which is imperative to understanding the cancer risk posed to humans. For most mutagenic impurities without

Evaluating the potential toxicity of chemicals is an important part of the drug development process. Optimizing a data set that provides quality over quantity is critical in the search for suitable drug candidates. Developed by our scientists, Vitic is a chemical database and information management system that provides rapid access to high-quality toxicity data from

By 2025, 36% of world data will be healthcare data. (Yes, thirty-six percent!). Considering this statistic, now more than ever, it is important that we are working to ensure existing data is utilised to make better safety assessment decisions more quickly – whilst also relying less on animal testing. Within many sectors of the life